Lymphoblastic Lymphoma
Conditions
Brief summary
Retrospective observational study with systematic collection of data on filiation (age at diagnosis and sex), clinical data (IPI, ECOG, early response to chemotherapy, overall response to chemotherapy), biological (strain B or T, infiltration of the nervous system central \[CNS\], bone marrow \[MO\], lactate dehydrogenase (LDH) level at the time of diagnosis, as well as genetic patients included in the study, as well as the PETHEMA protocol used in the treatment of same patients The study will review the PETHEMA protocols from 2003 to the present
Detailed description
Retrospective observational study with systematic collection of data on filiation (age at diagnosis and sex), clinical data (IPI, ECOG, early response to chemotherapy, overall response to chemotherapy), biological (strain B or T, infiltration of the nervous system central \[CNS\], bone marrow \[MO\], lactate dehydrogenase (LDH) level at the time of diagnosis, as well as genetic patients included in the study, as well as the PETHEMA protocol used in the treatment of same patients The study will review the PETHEMA protocols from 2003 to the present. Analysis of the main clinical-biological variables as independent risk factors in adult patients (\> 15 years) diagnosed with ALL
Interventions
None listed
Sponsors
PETHEMA Foundation
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
15 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Patients \>15 years old diagnosed with ALL and treated with the PETHEMA protocols for ALL
Exclusion criteria
None
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Description pronostic factors | 1 year | Study of the main clinical-biological variables as independent risk factors in adult patients (\> 15 years) diagnosed with ALL |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| overall survival | 1 year | To study if there has been an increase in overall survival (OS), in patients diagnosed with ALL in the different PETHEMA protocols |
| Progression free survival | 1 year | To study if there has been an increase in progression-free survival (PFS) in patients diagnosed with ALL in the different PETHEMA protocols |
Countries
Spain
Contacts
Primary ContactMiguel Sagüés Serrano, Dr
Backup ContactJosep Mª Ribera, Dr
Outcome results
None listed